Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatment

Launched by CENTRE FRANCOIS BACLESSE · May 31, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on studying a new way to understand and treat triple-negative breast cancer, which is a type of breast cancer that does not respond to some common treatments. Researchers are using a special technique called organoids, which are tiny, lab-grown versions of tumors that help scientists see how the cancer behaves and how it might respond to different therapies. The goal is to find out if these organoids can predict how well a patient might respond to new treatments, particularly those targeting specific genetic features of the cancer.

To participate in this trial, women aged 18 and older with early-stage triple-negative breast cancer who are about to start chemotherapy may be eligible. Participants will need to be proficient in French and agree to join the study by signing a consent form. Those who are pregnant, have a history of other cancers in the past five years, or are under legal guardianship cannot participate. By taking part, patients will contribute to vital research that could lead to better, more personalized treatment options for future patients with this challenging cancer.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patient over 18 years of age
• • Patient with early stage (I-III) triple negative breast cancer who needs to have clips placed before neoadjuvant chemotherapy
• • Patient affiliated to a social security system
• • Proficiency in French language,
• • Patient having signed the consent to participate in the study.
• Exclusion Criteria:
• • Pregnant women
• • Persons deprived of liberty or under guardianship (including curatorship)
• • History of any other clinically active malignancy in the last 5 years prior to inclusion